Chronic obstructive pulmonary disease treated with inhaled medium- or high-dose corticosteroids: A prospective and randomized study focusing on clinical efficacy and the risk of Pneumonia

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 601-607

  Ccheng, Shih Llung ^a,b   Su, Kang Cheng ^c   Wang, Hao Chien ^d   Perng, Diahn Warng ^c   Yang, Pan Chyr ^d  

^a Department of Iinternal Medicine Far Eeastern Memorial Hhospital ^*  (Taiwan)

^b YUAN ZE UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Chronic obstructive pulmonary disease; Inhaled corticosteroids; Pneumonia

Indexed keywords

FLUTICASONE; SALMETEROL; CORTICOSTEROID;

ADVERSE OUTCOME; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC OBSTRUCTIVE PULMONARY DISEASE ASSESSMENT TEST; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PNEUMONIA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; CHEMICALLY INDUCED; COMPLICATION; DOSE RESPONSE; INHALATIONAL DRUG ADMINISTRATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; PNEUMONIA; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS;

EID: 84901663502     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S63100     Document Type: Article

References (45)

1. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012;379:1341-1351.
2. Hunninghake GW, Crystal RG. Cigarette smoking and lung destruction. Accumulation of neutrophils in the lung of cigarette smokers. Am Rev Respir Dis. 1983;128:833-838.
3. Kanazawa H, Kurihara N, Hirata K, Fujimoto S, Takeda T. The role of free radicals and neutrophil elastase in development of pulmonary emphysema. Intern Med. 1992;31:857-860.
4. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003;22: 672-688.
5. Cosio MG, Majo J, Cosio MG. Inflammation of the airways and lung parenchyma in COPD: role of T cells. Chest. 2002;121:160S-165S.
6. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbation. Thorax. 2000;55:114-120.
7. Fry AM, Shay DK, Holman RC, Curns AT, Anderson LJ. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. JAMA. 2005;294:2712-2719.
8. Farr BM, Bartlett CL, Wadsworth J, Miller DL. Risk factors for community-acquired pneumonia diagnosed upon hospital admission. British Thoracic Society Pneumonia Study Group. Respir Med. 2000;94: 954-963.
9. Restrepo MI, Mortensen EM, Pugh JA, Anzueto A. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J. 2006;28:346-351.
10. Holguin F, Folch E, Redd SC, Mannino DM. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest. 2005;128:2005-2011.
11. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:74-81.
12. Spencer S, Calverley PMA, Burge PS, Jones PW. Impact of preventing exacerbation on deterioration of health status in COPD. Eur Respir J. 2004;23:698-702.
13. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet. 2003;361:449-456.
14. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187: 347-365.
15. Global initiative for chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management, and Prevention of COPD. Bethesda (MD): GOLD; 2013. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf. Accessed April 12, 2014.
16. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300: 2407-2416.
17. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009;169:219-229.
18. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med. 2007;176:162-166.
19. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775-798.
20. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180: 741-750.
21. Sin DD, Tashkin D, Zhang X, et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet. 2009;374: 712-719.
22. Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs. 2009;69:549-565.
23. Tashkin DP, Rennard SI, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs. 2008;68: 1975-2000.
24. Chen D, Restrepo MI, Fine MJ, et al. Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Am J Respir Crit Care Med. 2011;184:312-316.
25. Cheng SL, Wang HC, Cheng SJ, Yu CJ. Elevated placenta growth factor predicts pneumonia in patients with chronic obstructive pulmonary disease under inhaled corticosteroids therapy. BMC Pulm Med. 2011;11:46.
26. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34:648-654.
27. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645-2653.
28. Ozol D, Aysan T, Solak ZA, Mogulkoc N, Veral A, Sebik F. The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients. Respir Med. 2005;99:1494-1500.
29. MacRedmond RE, Greene CM, Dorscheid DR, McElvaney NG, O'Neill SJ. Epithelial expression of TLR4 is modulated in COPD and by steroid, salmeterol and cigarette smoke. Respir Res. 2007;8:84.
30. Zanini A, Chetta A, Saetta M, et al. Bronchial vascular remodeling in patients with COPD and its relationship with inhaled steroid treatment. Thorax. 2009;64:1019-1024.
31. Sims MW, Tal-Singer RM, Kierstein S, et al. Chronic obstructive pulmonary disease and inhaled steroid alter surfactant protein D (SP-D) levels: a cross-sectional study. Respir Res. 2008;9:13.
32. Yawn BP, Li Y, Tian H, Zhang J, Arcona S, Kahler KH. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int J Chron Obstruct Pulmon Dis. 2013;8:295-304.
33. Thornton Snider J, Luna Y, Wong KS, et al. Inhaled corticosteroids and the risk of pneumonia in Medicare patients with COPD. Curr Med Res Opin. 2012;28:1959-1967.
34. Ryan M, Suaya JA, Chapman JD, Stason WB, Shepard DS, Thomas CP. Incidence and cost of pneumonia in older adults with COPD in the United States. PLoS One. 2013;8:e75887.
35. Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68:1029-1036.
36. Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med. 2008;102:1099-1108.
37. Anzueto A, Ferguson GT, Feldman G, et al. Effect of fluticasone propionate/samleterol (250/50) on COPD exacerbation and impact on patient outcomes. COPD. 2009;6:320-329.
38. Malo de Molina R, Mortensen EM, Restrepo MI, Copeland LA, Pugh MJ, Anzueto A. Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia. Eur Respir J. 2010;36:751-757.
39. Singanayagam A, Chalmers JD, Akram AR, Hill AT. Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia. Eur Respir J. 2011;38:36-41.
40. Kim JH, Park JS, Kim KH, Jeong HC, Kim EK, Lee JH. Inhaled corticosteroid is associated with an increased risk of TB in patients with COPD. Chest. 2013;143:1018-1024.
41. Lee CH, Kim K, Hyun MK, Jang EJ, Lee NR, Yim JJ. Use of inhaled corticosteroids and the risk of tuberculosis. Thorax. 2013;68: 1105-1113.
42. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123:1001-1006.
43. O'Byrne PM, Rennard S, Gerstein H, et al. Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids. Respir Med. 2012;106:1487-1493.
44. Dendukuri N, Blais L, LeLorier J. Inhaled corticosteroids and the risk of diabetes among the elderly. Br J Clin Pharmacol. 2002;54:59-64.
45. Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med. 2002;17:717-720.